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Summary 
A landmark in European regulation of pharmaceuticals
will be reached on 26 January 2005. It is forty years
since the first Directive on the regulation of medicinal
products was adopted. Council Directive 65/65/EEC
was published in the Official Journal of the EC on 9
February 1965.1
This fundamental Directive is a reflection of the re-
action of the EEC and its six Member States to the
world-wide disaster involving the use of thalidomide at
the time. The marketing authorisation procedures even
of many non-EEC countries, including those of Finland,
for example, have their origins in the 1960s. The two
options of the European system for the authorisation of
medicinal products were even at that time the cen-
tralised and decentralised marketing authorisation pro-
cedures. However, the initial resolution focused only on
harmonising the national procedures and the scientific
evaluation criteria.
The first pharmaceutical directive was argumented
by the need to safeguard public health and promote the
internal markets – the most recent EU pharmaceutical
legislation is also sustained by the same basic principles.
The principles adopted forty years ago still largely re-
main the mainstay of the EU regulation of medicines.
The most important principle of them all is perhaps the
stipulation that a medicinal product cannot be sold or
marketed unless it has a marketing authorisation ap-
proved by the authorities. Another essential principle is
that issues relating to the efficacy, safety and quality of
the product can be the sole grounds for considering a
marketing authorisation.
It was as important 40 years ago as it is now that
the authorities should have a carefully specified time
limit within which to grant the marketing authorisation
and that, once granted, the marketing authorisation
cannot be cancelled other than on the grounds given in
the directive. The incorporation of these principles in
the national legislation took several years in many coun-
tries. In Finland, the principles were adopted in associa-
tion with the EEA agreement in 1994.
With the enlargement of the EU through the decades
the regulation of pharmaceuticals and the pharmaceuti-
cal legislation in Europe became more profound in
many respects. The procedures of approval and regula-
tion have become centralised, and closer collaboration
between Member States has been established. The pre-
sent EU regulation of medicines covers several specific
categories of medicines. Examples of them include
biotechnological medicinal products, orphan medicinal
products, traditional herbal medicinal products and the
proposed Regulation on paediatric medicinal products.
Veterinary medicinal products are also an essential part
of the regulation of medicines.
The cost of developing a new innovative medicine is
estimated at about 800 million US dollars. There has
been an exponential rise in the research and develop-
ment costs. At the same,  the pharmaceuticals regulation
and the internal market have improved. Important new
innovations from the pharmaceutical industry, both in
Europe and the USA, are not seen as often as they used
to be. Justifiably, the question has been raised whether
the research and development cost of a new medicine
could be reduced and whether we should address the is-
sue of the authorities’ requirements for scientific and
other evidence in association with marketing authorisa-
tions.2
It has also been suggested that the authorities appear
to have ’ritualistic’ requirements, the original grounds
for which nobody any longer properly knows.
Unnecessary and groundless rituals in the authorisa-
tion of medicinal products – where they exist – should
of course be abandoned. However, it makes sense and is
preferable in general in the authorisation of medicines
to pursue with caution rather than in a hazardous fash-
ion. It appears that breakthrough innovations increasing
the wellbeing of mankind are being made irrespective of
the stipulations imposed by the regulation of medicines,
or – at best – with the help of the stipulations.
1 Council Directive 65/65/EEC of 26 January 1965 on the ap-
proximation of provisions laid down by law, regulation or ad-
ministrative action relating to proprietary medicinal products.
OJ No 22, 9.2.1965.
2 Rawlins MD: Cutting the cost of drug development? Nature
Drug Discovery 3:360-364, April 2004.
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Bromocriptine, cabergoline and per-
golide are ergot derivatives, whereas
products such as quinagolide,
pramipexole and ropinirole do not
have an ergot radical. Clinical use of
the drugs is based on the concept
that they have an effect on the nerve
tissue similar to that of dopamine.
They are all D2 receptor stimulants
with varying effects on D1 and D3
(Table) and non-dopaminergic
receptors. Ropinirole is selectively
bound to dopamine receptors,
pramipexole has a mild effect on
noradrenergic alpha2 receptors and
ergot derivatives are also bound to
noradrenergic (alpha1 and alpha2)
and 5HT receptors.
Dopamine effect
The most common adverse effects of
dopamine agonists are associated
with their dopaminergic effects.
These effects often occur at the start
of treatment or are transient follow-
ing an increase in the dose, and
most of them are similar to one
another. The adverse effects include
nausea, vomiting, orthostatic
hypotension, vertigo, somnolence
and (in concomitant use with lev-
odopa) dyskinesia (2). Common
reactions also include insomnia,
constipation, abdominal pain, indi-
gestion and feeling weak. Dopamine
like substances may on long-term
use also cause confusion, hallucina-
tions or paranoia, especially in indi-
viduals with impaired cognitive
function. The rarer reactions include
compulsive gambling and hypersex-
uality, priapism, reduced breast size
and alopecia. Headache, nasal con-
gestion and Raynaud’s syndrome
may also occur in patients on ergot
derivatives. Efficacy and tolerability
do not seem to vary considerably
between the various dopamine ago-
nists, even though, admittedly, com-
parisons have been made only with
bromocriptine (3).
Some of the more recent adverse
effects are discussed below.
Disturbances of alertness
Increased daytime sleepiness,
increased frequency of nodding off
and sudden sleep attacks have been
reported with the use of dopamine
agonists, especially in Parkinson’s
disease (4, 5). The problem has
attracted special attention recently,
since in 1999, a couple of patients
were reported as having suddenly
fallen asleep while driving.
In various studies (5) sleepiness
has been reported in 18.3–32.4% of
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Summary 
Neurologists all over the world are concerned about the safety of the use of dopamine receptor 
agonists, since hitherto unknown and potentially life-threatening adverse effects have been de-
scribed in association with drugs which have been in use for years (1). Dopamine agonists are used
in the treatment of Parkinson’s disease, restless legs syndrome, hyperprolactinaemia and
acromegaly.
Propert ies of  dopamine agonists
Bromocriptine Cabergoline Pergolide Quinagolide Pramipexole Ropinirole
Receptor
binding D1, D2, D3 D1, D2 D1, D2, D3 D2 D2, D3 D2, D3
Ergot derivative Yes Yes Yes No No No
Tmax (hours) 1–2 0.5–4 1.5 0.5–1 2
T1/2  (hours) 3–8 68 1–42 12–18 8–12 6
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patients on pramipexole and in
8.8–13.7% of patients on a placebo.
It has been more common in
patients using pramipexole than in
the levodopa group of patients
(17.3%) (6). Sleepiness was associat-
ed with ropinirole therapy in 36.2%
of patients and in 4.8% of patients
in the placebo group (7). It occurred
mostly as the dose of medication
was increased and at higher daily
doses.
Despite the more prominent role
of the more recent non-ergot ago-
nists, there is a similar problem with
the rest of the agonists (8, 9) and it
seem apparently that the differences
among the various drugs are not all
that significant.
A sudden compulsive sleep
attack, where falling asleep happens
either without warning or so quickly
that the person has no time to react
properly, appears to be rarer than
the irresistible need to fall asleep,
where the person is able to react
appropriately. In a study of 420
patients, Hobson et al. (10) reported
sudden attacks of sleep in 16
patients while driving (3.8%), in
three of whom (0.7%) this occurred
without warning. The percentages
are likely to show the overall ten-
dency, and they correlate with the
duration of the monitored period. If
sudden sleep attacks occur, the
patient should avoid driving.
Patients should also be advised
about it at the start of the treatment.
Oedema in the lower extremities
Oedema in the lower extremities
(‘pitting oedema’) is a common
problem associated with all
dopamine agonists and in many
patients has resulted, for example, in
investigation for causes of cardiac
origin. Among the more recent ago-
nists, it is perhaps associated a little
less with the use of ropinirole (11).
The underlying biology of the prob-
lem is unknown, but it may be asso-
ciated with the vasodilatory effect of
dopamine.
Neuroleptic malignant syndrome
A condition similar to neuroleptic
malignant syndrome may easily
develop if medication is suddenly
stopped. The clinical signs of this
rare problem include fever, muscular
rigidity, fluctuating level of con-
sciousness and various disturbances
of the autonomic nervous system
(tachycardia, sweating, blood pres-
sure changes, hypoventilation and
elevated serum creatine kinase (12).
Adverse effects on the lungs and
connective tissues
Ergot derivatives (bromocriptine,
cabergoline and pergolide) have for
a long time been known to cause
pulmonary, pericardial and retro-
peritoneal pleuritis and fibrosis (13,
14). Upon discontinuation of the
medication, the pleural fluid disap-
pears, but fibrosis may result in
reduced respiratory function.
The summaries of product char-
acteristics give the impression that
the problem is relatively rare, and
according to the adverse drug reac-
tion register the frequency with per-
golide is about 1% in relation to the
use of the drug (13). Between 1982
and 1995, in the Department of
Neurology of Helsinki-Uusimaa
Hospital District, 33 of the total of
185 long-term patients with Parkin-
son’s disease receiving mainly
bromocriptine or pergolide therapy
were diagnosed as having pleuritis
for an average period of 6 months
(15). An ergot agonist was being
used experimentally in four of the
patients. The problem therefore
appears to be far more common
than is obvious from the adverse
drug reaction register, and a conser-
vative estimate shows that the risk
in long-term treatment may be over
10%. It may be that Finns are espe-
cially sensitive; after all, the very
first report of an adverse reaction
was made in Finland in 1981 (16).
Adverse effects on the connective
tissues have also been reported in
patients who have been given an
ergot agonist for the suppression of
prolactin (17) or for the treatment
of restless legs (18). Fewer adverse
effects in these reports could indi-
cate that the problem is dose depen-
dent.
Non-ergot agonists are not
expected to be associated with the
problem of fibrosis. Patients with
Parkinsonism previously suffering
from ergot-pleuritis (N=11) have
been treated (15) with a non-ergot
agonist (quinagolide) without diffi-
culty for an average of 620 days fol-
lowed by pramipexole therapy when
it became available in the autumn of
1998. The phenomenon has not
been shown in the use of pramipex-
ole or ropinirole, except in some iso-
lated cases with an unclear causal
relationship.
Cardiac valve changes
Cardiac valve changes have very
recently been reported in patients
with Parkinson’s disease treated
with pergolide and carbergoline;
some of the cases have been fatal
(19-20).  According to a review
recently published (22), the problem
may actually be very common. Base-
man et al. (22) sent a letter to
patients whom they knew to be
using pergolide advising them to
undergo cardiac examination. Forty-
six of the recipients of the letter did
as advised, and the researchers
reported that 89% of the patients
were suffering from some degree of
cardiac valve regurgitation. Inci-
dences of valvular regurgitation
have been fewer in patients in Cen-
tral-Europe compared with the USA,
but the disorder still affects 33% of
patients (23). Since  migraine treat-
ment with ergot derivatives (24) and
the use of bromocriptine (25) have
also been reported as having been
associated with corresponding
changes, a risk of a side effect char-
acteristic of all ergot derivatives can
be assumed, and all colleagues
should be made aware of this. The
actual extent of the problem will
perhaps be revealed in the course of
time.
Ergot pleuritis does not cause
fever in the patients; the CRP and
the ESR are elevated, but there is no
leucocytosis. The authors have no
information about laboratory results
in patients with cardiac valve disor-
der.
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The cardiac action potential normal-
ly lasts for 200–300 milliseconds. As
it is corrected according to the heart
rate (QTc), the terms QT interval
and QTc interval are used as syn-
onyms in this article for the sake of
simplicity. A QT interval prolonga-
tion over 440-460 milliseconds can
cause ventricular fibrillation which,
if left untreated, causes sudden death
in about 20–25% of the patients.
Ventricular fibrillation is in the ECG
curve preceded by torsades de
pointes type ventricular tachycardia.
There are two forms of the long 
QT syndrome, a congenital and an
acquired one. The congenital form
has seven different known predispos-
ing genes, six of which are associated
with the myocardial ion channels.
The prevalence of the congenital
form is estimated at less than
1/10000. Among the congenital
forms, particular interest is focused
on the potassium channel coded by
the HERG gene located on chromo-
some 7 and with a key role in the
normal electric cardiac activity. The
potassium channel coded by the
HERG gene is partly responsible for
the return of the electric cardiac
activity to the resting phase before
the next myocardial electric activa-
tion process. Disturbed function will
prolong the return to the resting
phase, which is thought to be an
essential part of the development
mechanism of myocardial torsades
de pointes tachycardia. There may
also be a correlation between the
strength of binding of the medicinal
substance to the potassium channel
coded by the HERG gene and pro-
longation of the QT interval.
When talking about an acquired
QT prolongation, we mean the pro-
longation of the QT interval caused
by drugs, examples of which include
the effects of antiallergics such as
astemizol and terfenadine. Even
though several of the drugs affecting
the QT interval are used only at cer-
tain seasons, the treatment periods
may exceptionally be long-drawn-
out. Another drug with QT interval
prolonging properties recognised in
the beginning of the 1990s, was cis-
apride. As it is difficult to predict the
effects of various drugs on the QT
interval, European drug regulation is
focusing on the issue, and in future
documentation on the effects of
drugs on the QT interval even prior
to the granting of a marketing
authorisation will probably become
part of drug safety procedures. In
addition, interpretation of the effects
is made difficult by the combined use
of drugs, as a drug which may not
have an effect on the QT interval
when used alone may very well have
one when used together with another
medicinal product.
Drugs with a known effect on the
QT interval include e.g. some anti-
arrhythmics, terfenadine and astemi-
zol, and also some of the antidepres-
sants, antipsychotics and antimicro-
bials (Table).
During 1981–2004 the NAM
received a total of 58 reports on QT
interval prolongation. Thirteen of
the reports were on torsades de
pointes ventricular tachycardia, 12
were on ventricular fibrillation, four
on cardiac arrest, and one of the
cases was fatal.
In addition, two reports were of
a suspected interaction between ter-
fenadine and itraconazole, and one
on tamsulocine. There were two
reports on cisapride, two on ceti-
rizin, and one on ebastine used con-
comitantly with doxepine. According
to ATC system, the most frequently
suspected groups of drugs were
antipsychotics (21 reports), antide-
pressants (11 reports) and sotalol (6
reports).
Several drugs have been with-
drawn from the market due to the
risk of arrhythmia. However, the
relationship between the HERG
gene, QT interval prolongation and
torsades de pointes ventricular tachy-
cardia is also complicated owing to
the difficulty, if not the impossibility
of assessment and prediction of the
causal relationship. Despite the asso-
ciation which exists between the
HERG gene, the potassium channel
coded by it and the QT interval pro-
longation, there is at present no
definitive proof of a link between
these three factors. Obviously, as far
as drug safety is concerned, drug
effects such as severe cardiac
arrhythmia are a major challenge to
the medicinal product regulation sys-
tem, especially in the light of precau-
tionary measures. An example of an
attempt to classify medicinal sub-
stances according to the QT interval
prolongation they may possibly
cause, is the website of the Universi-
ty of Arizona; The University of Ari-
zona Health Sciences Center.
http://www.qtdrugs.org/. 
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Most commonly reported drugs 
Medicinal substances        No of reports
Sotalol 6 
Sertindol 6 
Risperidone 6 *
Venlafaxine   5 
Terodiline 4
Thioridazine 4 **
*  three of the reports also included other
suspected drugs
** two of the reports also included other sus-
pected drugs
Cardiac QT interval prolongation and drugs
The tendency of the total consump-
tion of antimicrobials to decrease
during the past decade is probably
due to that courses of antiobiotics
have been shortened. The variations
in severity of the epidemics caused
by viruses every winter is neverthe-
less immediately visible from the use
of antimicrobials (1). Considerable
annual fluctuations are consequently
revealed by their use. 
A review of the results of the
MIKSTRA Program carried out dur-
ing 1998–2002 is under way. Once
the review is ready, it will reveal
more detailed information on the
use of antimicrobials and the indica-
tions for which they have been used
in Finland. It is already known that
there has been no reduction in their
use for the treatment of acute bron-
chitis (2). Acute bronchitis is still of-
ten unnecessarily treated with an-
timicrobials despite the fact that it is
a viral disease. But the treatment
recommendations relative to urinary
tract infections, in particular with
respect to the choice of drug, have
been closely followed (3).
Penicillins
According to the Finnish Statistics
on Medicines (www.nam.fi/) signifi-
cant changes have taken place in the
various uses of antimicrobials dur-
ing the 1980s and 1990s (Fig. 1).
The use of penicillin V has been re-
duced by a half during a little over a
decade. Its use may have been re-
placed mostly by amoxicillin. This
has all been in line with the current
treatment recommendations, since
the treatment recommendations, es-
pecially for acute otitis and maxil-
lary sinusitis, now also include
amoxicillin alongside penicillin as
the primary drug. The easier use of
amoxicillin, especially in the treat-
ment of infections in children, may
also have contributed to its in-
creased use.
An increase in the use of amoxi-
cillin-clavulanic acid also has been
seen in recent years. In the treatment
recommendations, however, this is
distinctly treated as a secondary
drug. The increased use may be ex-
plained by the fact that respiratory
tract infections are considered by
doctors more often to be caused by
bacteria which produce betalacta-
mase. The production of betalacta-
54 TABU 6.2004
Pentti Huovinen
D.MED.SC., RESEARCH PROFESSOR
Laboratory of Infection Immunity
Department of Human Microbial Ecology and Inflammation 
National Public Health Institute
Macrolides and fluoroquinolones – target of 
improved monitoring
Over more than a decade the use of antimicrobials in out-patient care has fallen by about 10%.
Despite the positive development overall, the use of antimicrobials in Finland still exceeds that in
the other Nordic countries. The correct choice of antimicrobials in accordance with treatment rec-
ommendations and the length of the courses of treatment particularly need to be focused on. The
targets for special monitoring are the use of macrolides and fluoroquinolones, including monitor-
ing of the development of resistance.
Fig.  1 .  Consumption of  most  common antimicrobials  in  F inland 1990–2003
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mase by bacteria such as
Haemophilus influenzae and
Moraxella catarrhalis has not, how-
ever, increased during the past seven
years, but rather diminished
(www.ktl.fi/extras/fire). The efficacy
of amoxicillin-clavulanic acid
against pneumococcus is equal to
that of amoxicillin alone. Grounds
for the increased use of amoxicillin-
clavulanic acid are therefore difficult
to find.
Cephalosporins
Cephalosporins are rather widely
used in Finland, compared with oth-
er European countries
(http://www.ua.ac.be/main.asp?c=*E
SAC ). The consumption profile is,
however, totally different compared
to that of other European countries.
The ones used in Finland are mainly
first-generation cephalosporins con-
centrating on the treatment of infec-
tions of the skin and of the respira-
tory tract. The treatment of skin in-
fections with first-generation
cephalosporins mainly follows the
current treatment recommendations.
In the treatment of respiratory tract
infections, however, first-generation
cephalosporins do not have primary
indications. Their efficacy against
pneumococcus is not superior to
that of amoxicillin or penicillin V,
and the efficacy against Haemo-
philus is poorer than that of amoxi-
cillin. In the treatment of tonsillitis,
first-generation cephalosporins have
often been regarded as a primary
drug equivalent to penicillin. At the
present time they are still defined as
a secondary choice in the current
treatment recommendations.
Second- and third-generation
cephalosporins are hardly ever used
in out-patient care in Finland. This
is excellent. Their clinical efficacy in
the treatment of out-patient infec-
tions is not superior to that of the
primary drugs included in the treat-
ment recommendations. Further-
more, their oral administration is as-
sociated with a host of gastrointesti-
nal adverse effects. The avoidance of
these drugs has also delayed the de-
velopment of bacterial resistance.
Sulfa-trimethoprimes
Products containing sulfonamide
alone were quietly withdrawn from
the Finnish market around the mid-
1990s. That marked the end of the
journey as far as its use went as an
independent product of the first an-
timicrobial developed by humans.
The use of the sulfa-trimethoprim
combination is also modest. The
fear of the serious adverse effects of
sulfonamides and the development
of resistance are the main reasons
for the decreased use. Sulfa-trimeth-
oprim is nevertheless still an impor-
tant secondary or third alternative in
the treatment for otitis and perhaps
even for sinusitis. The situation with
regard to the sensitivity of respirato-
ry pathogens is also somewhat im-
proved compared with that five
years ago.
Trimethoprim has retained its
position as a primary drug in uri-
nary tract infections (3). The sensi-
tivity to trimethoprim of E. coli sep-
arated from urinary samples has al-
so increased rather than decreased.
Trimethoprim, side by side with
mecillinam, is the drug most com-
monly used in urinary tract infec-
tions.
Tetracyclines
As with penicillin V and sulfa-
trimethoprim, the use of tetracy-
clines has also declined during re-
cent years. Tetracyclines are the con-
ventional drugs in the treatment of
respiratory tract infections. The use
of tetracyclines has been replaced
partly by macrolides and partly by
amoxicillin. The sensitivity to tetra-
cyclines of bacteria causing respira-
tory tract infections still remains
good, however, despite their contin-
uous use for decades. The position
of tetracyclines could therefore be
reviewed in the next update of the
current treatment recommendations,
especially in regard to the treatment
of adult otitis and sinusitis. This
would reduce the pressures to use
macrolides and other secondary
drugs.
Macrolides
The use of macrolides was cut by al-
most a half during 1992–1994 as a
result of the recommendations given
in association with the increase in
the macrolide resistance of Strepto-
coccus A bacteria (Fig. 2). For now,
the use of macrolides has reverted to
almost the same level as that at
which it was during 1990–1991. It
remains to be seen whether the con-
siderable increase recently reported
in the macrolide resistance of pneu-
mococci has any effect on drug use
(4, 5). In order to halt the increase
in the resistance of pneumococci, the
use of macrolides should be signifi-
cantly decreased in the treatment of
infections caused by pneumococci.
The preconditions for this are good,
since macrolides are only rarely used
as primary drugs in the treatment of
infections in out-patient care. To-
gether with the increase in the
macrolide resistance, the efficacy of
these drugs against pneumococci isFig. 2. Consumption of macrolides in out-patient care in Finland 1990–2003
also reduced. The use of macrolides
and the development of the situation
regarding bacterial resistance will
continue to be closely monitored in
the years to come.
Fluoroquinolones
The increased use of fluoroquinol-
ones is a result of the increase in the
use of both levofloxacin and
ciprofloxacin (Fig. 3). The use has
nevertheless remained relatively
steady during the last four years.
Norfloxacin and ciprofloxacin are
probably mostly used in the treat-
ment of urinary tract infections. In
urinary tract infections fluoro-
quinolones are nevertheless a sec-
ondary drug group, in which posi-
tion they have also remained accord-
ing to the results of MIKSTRA.
According to the Finnish Statis-
tics on Medicines 2003, 43% of the
levofloxacin used is used in out-pa-
tient care. A closer study on the in-
dications for use is not available at
present. However, levofloxacin re-
mains a drug in reverse for the treat-
ment of respiratory infections and it
should only be used in special cases.
The increase in the use of fluoro-
quinolones is already apparent in
some areas in the form of an in-
creased resistance of urinary tract 
E. coli bacteria. The fluoro-
quinolone resistance of Neisseria
gonorrhoea in 2003 was approxi-
mately 20%. A large proportion of
Campylobacter are resistant to fluo-
roquinolones, and the degree of sen-
sitivity of Salmonella is also falling.
According to experience in other
parts of the world, the increased use
of fluoroquinolones in the treatment
of respiratory infections has also
been apparent in the level of resis-
tance of pneumococci. Consequent-
ly, the use of fluoroquinolones and
the state of the resistance to them
are also closely monitored in Fin-
land.
Conclusion
The changes in the use of antimicro-
bials reflect in many ways the spirit
of the current treatment recommen-
dations in Finland. Positive changes
include the reinforced position of
amoxicillin for otitis and sinusitis
and the recommended treatment
practice for urinary tract infections. 
Negative developments include
the increased use of macrolides and
the increase in the macrolide resis-
tance of pneumococci. The use of
fluoroquinolones has also more than
doubled, already with associated
emerging problems of resistance. 
The position of tetracyclines in
the treatment of respiratory infec-
tions could be reviewed, especially
since the level of resistance to other
drugs used for these infections is
gradually making those less effec-
tive.
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Fig.  3.  Consumption of  most  common quinolones in F inland 1990–2003
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In the public debate of the pros and
cons of various medications it is
often forgotten that many modern
drugs are derived from herbs and
plants (table 1). 
With the emergence of modern
chemistry the active ingredients of
medicinal plants, such as those
above, were extracted and purified.
Consequently for the last century
there has been an emphasis on the
use of purified or purpose made
preparations to achieve predictable
therapeutic goals. This approach has
been extremely effective and has
facilitated an unforeseen develop-
ment of new therapies. Nevertheless,
there is a worldwide resurgence of
“traditional” therapies.
These trends are clearly evident
also in Australia. Complementary
medicine, is now gaining the atten-
tion of the broader health care sec-
tor and the regulatory agencies. The
Australian Medical Association
(AMA) defines the term complemen-
tary medicine as a wide range of
non-prescription products with
health claims such as herbal medi-
cines, homoeopathic medicines,
nutritional and other supplements
such as vitamins and minerals. 
Complementary therapies“ include
acupuncture, chiropractic, osteopa-
thy, naturopathy, aromatherapy,
reflexology, iridology, kinesiology
and meditation” (2). Often the term
complementary medicine refers to
both complementary medicines and
therapies.
The Therapeutic Goods Adminis-
tration of Australia (TGA) defines
complementary medicine as “a
regime for the prevention or allevia-
tion of a disease or ailment, or for
the maintenance of health, and
which does not necessarily rely on
evidence of efficacy based on West-
ern medical practice” (3).
These definitions are in line with
the World Health Organization,
who defines complementary and
alternative medicine (CAM) as a
broad set of health-care practices
that are not part of a country’s own
tradition and not integrated into the
dominant health care system (1).
Whilst this definition may be accu-
rate, soon it may need to be revised
as the use of complementary medi-
cine continues to increase and in
some countries exceeds the use of
conventional medicine. 
Historic transition to modern
therapies
The pharmacological treatment of
disease emerged long ago with the
use of herbs (4). Herbs were an
important part of traditional folk
healing throughout the world. By
definition traditional use of herbal
medicines, implies significant histori-
cal use. Complementary medicines
have maintained their popularity for
historical and cultural reasons irre-
spective of efficacy. However, these
products have become much more
widely available commercially, espe-
cially in developed countries. The
commercial marketing of comple-
mentary medicines has led to uses
that were never contemplated in the
traditional healing systems. The use
of ephedra (Ephedra sinica, Chinese
Ephedra, Ma huang) for weight loss
or athletic performance is a good
example of this (5).
Resurgence of complementary
medicines and therapies
Whilst complementary medicine has
maintained its place in all regions of
the developing world for historical
reasons but also out of necessity, in
the industrialized countries the rapid
growth of their use is occurring for
other reasons (table 2).
Use of complementary medicine
in Australia
There has been a sharp increase in
the expenditure for complementary
Jorma Ahokas and Danielle Sevior
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Complementary medicine in Australia
‘Complementary therapies’ or ‘Alternative therapies’ were not always known as complementary or
alternative. In the past these were the only available therapeutic agents. Traditionally plant, some-
times animal or mineral derived products were used for therapeutic purposes. In many developing
countries patient care still relies extensively on herbal or similar preparations. The World Health
Organization estimates that the extent of this reliance is as high as 80%. (1).
Table 1 .  Examples of  drugs derivated from herbs
Salicylates (‘aspirin’) Willow bark (Salix sp.)
Opium (morphine, codeine) Poppy (Papaver somniferum)
Digitalis Foxglove (Digitalis purpurea)
Scopolamine Angels trumpets (Brugmansia suaveolens)
Atropine Belladonna (Atropa belladonna/Deadly nightshade)
Colchicine Colchicum (Colchicum autumnale)
Cocaine Coca leaves (Erythroxylum coca)
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medicine in Australia. Over 52% of
the population use complementary
medicines and 23% visit practition-
ers for complementary therapy. It is
estimated that in 2000 the Austral-
ian public outlaid $1,671 million on
complementary medicines, when by
comparison they outlaid $688 mil-
lion for prescription medications.
Figure compares the out of pocket
expenses of Australians on comple-
mentary therapies, complementary
medicine and prescription medica-
tion in Australia. Based on the fig-
ure it appears that there has been a
~2-fold increase in total expenditure
on prescription medicines between
1993 and 2000, and a ~3-fold
increase in expenditure on comple-
mentary medicines for the same
period. This data highlights the
increase in use and popularity of
complementary medicines in Aus-
tralia.
A significant proportion of com-
plementary medicines used in Aus-
tralia are herbal products. Table 3
shows the top 10 selling herbs by
pharmacies and supermarkets in
Australia for 2000–2001. This usage
pattern is very much in line with the
USA and other western countries.
Adverse effects
One of the greatest problems with
complementary medicine is that
many people consider them to be
intrinsically safe because they are
derived from natural sources. In the
study conducted by MacLennan (7),
90% of people who used comple-
mentary medicines considered them
to be safe. This belief in their safety
remains largely intact even though
there are 150–200 cases of adverse
reactions per year reported to the
Australian Government Adverse
Drug Reactions Advisory Committee
(ADRAC) (8). The main types of
adverse reactions reported to
ADRAC include headaches, skin
rashes, dizziness, nausea and gastro-
intestinal upsets (10).
Whilst the figure of 150–200 is
only a small proportion of the
12,000 adverse reactions reported to
the ADRAC annually, it should be
noted that complementary medicines
have only been recently added to the
ADRAC list. Other reasons for the
low number of adverse effects
Table 2.  Observations regarding the increase in use and popular ity  of
complementary medicines according to the WHO (6)
•  25% of modern medicines are made from herbs first used traditionally.
•  In China, traditional herbal preparations account for 30–50% of the total medicinal
consumption.
•  In Ghana, Mali, Nigeria and Zambia, the first line of treatment for 60% of children
with high fever resulting from malaria is the use of herbal medicines at home.
•  In Europe, North America and other industrialized regions, over 50% of the popula-
tion have used complementary or alternative medicine at least once.
•  In San Francisco, London and South Africa, 75% of people living with HIV/AIDS use
complementary medicines.
•  70% of the population in Canada have used a complementary medicine at least
once.
•  In Germany, 90% of the population have used a natural remedy at some point in
their life. In Germany between 1995 and 2000, the number of doctors who had un-
dergone special training in natural remedy medicine had almost doubled to
10,800.
•  In the United States, 158 million of the adult population use complementary medi-
cines and according to the USA Commission for Alternative and Complementary
medicines, US $17 billion was spent on traditional remedies in 2000.
•  In the United Kingdom, annual expenditure on alternative medicine is US$ 230 mil-
lion.
•  The global market for herbal medicines currently stands at over US $ 60 billion an-
nually and is growing steadily.
The trends in out  of  pocket  expenses for  complementary therapies,
medicines and prescr ipt ion medicat ion in Austral ia  f rom 1993 to 2000.
The total cost of the Pharmaceutical Benefits Scheme (PBS) is given as a comparison
(the PBS is what the government in Australia contributes to the cost of prescription
medications).
Table 3.  Combined retai l  sales data for  supermarkets and pharmacies
in Austral ia  for  2000 and 2001. Adapted from Wohlmuth et al. (9)
Herbal product AUS Dollars % Share of herbals
Echinacea (Echinacea sp.) 15,500,000 13
Phytoestrogens 11,000,000 9
Evening Primrose Oil (Oenothera biennis) 10,000,000 8
Garlic/Horseradish
(Allium sativum/Radicula rusticana) 7,500,000 6
Valerian (Valeriana officinalis) 6,500,000 5
Ginko (Ginkgo biloba) 6,500,000 5
Hypericum (Hypericum perforatum) 6,500,000 5
Guarana 4,500,000 4
Celery (Apium graveolens) 4,500,000 4
Garlic (Allium sativum) 4,000,000 3
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reported include the ease of access
to products, lack of knowledge by
many practitioners and members of
the public as to what constitutes an
adverse effect. Self medication with
complementary medicines may also
lead to under-reporting of adverse
effects. However, the low number of
adverse reactions reported in rela-
tion to complementary medicines
cannot be taken as an indicator of
safety.
Causes of adverse effects
The increased use of complementary
remedies in western cultures has
resulted in their unregulated market-
ing and use. In some cases this has
lead to tragic consequences. In 1993
over 100 cases of irreversible
nephropathy were reported in young
women attending a slimming clinic
in Belgium. The nephrotoxicity was
traced to the accidental substitution
of Stephania tetandra with the high-
ly toxic Aristolochia fangchi. The
misidentification of other Aristol-
ochia species has occurred in the
United Kingdom, China and France
(11). Substitution of one ingredient
with another may be accidental due
to misidentification or deliberate.
Deliberate substitution with
other herbal products or illegal “for-
tification” with medicinal substances
may have dire consequences. The
addition of corticosteroid in creams
for the treatment of eczema, fenflu-
ramine in a slimming product and
prescription medicines such as silde-
nafil, glibenclamide, warfarin and
alprazolam in herbal products have
all been reported (11). 
In the modern mass marketing of
complementary medicines quality
standards in manufacturing are
important. Poor manufacturing stan-
dards are a health threat to the con-
sumer. In January 2003, questions
into the manufacturing and quality
control processes were raised by the
TGA with respect to a very large
Australian manufacturer of generic
and complementary medicines. Ini-
tially it was found that the content
of the active ingredient (hyoscine
hydrobromide) in motion sickness
tablets varied from 0–700% of the
listed dose. Under further scrutiny a
large number of irregular practices
emerged affecting both generic and
complementary products. Table 4
summarizes the findings of the
expert committee from the TGA
that investigated the manufacture
plant. In April 2003, there was a
large-scale recall of medicines
involving as many as 219 products.
The manufacturing license  was sub-
sequently suspended and now the
company has gone into liquidation.
There are many examples of
heavy metal contamination of com-
plementary medicines. Heavy metal
content may arise from contaminat-
ed raw materials, from processing
and manufacturing practices or be
added deliberately. In the latter case
it may be declared as a constituent
of complementary medicines. The
Chinese Pharmacopoeia lists formu-
lations for nearly fifty products that
include heavy metals such as arsenic
or mercury. 
“Tainted herbal tablets poison baby
The item above is of a case of heavy
metal contamination of complemen-
tary medicines reported in an Aus-
tralian newspaper:
“Doctors measured the highest yet
recorded lead level in a newborn
baby after a woman who had been
taking contaminated herbal tablets
gave birth in an Adelaide hospital.
The girl was born critically ill but
survived despite having a blood lead
concentration 25 times the maxi-
mum acceptable level.
Her 24-year-old mother, who
recently emigrated from India, had
for nine years been taking herbal
tablets prescribed to her by a doctor
skilled in Eastern medicine to treat a
stomach complaint. In the nine
months of her pregnancy, the
woman’s lead intake was estimated
to be at least 50 times the average
weekly intake of Western popula-
tions. The baby was born with an
abnormal brain condition known as
encephalopathy.” (The Age
19/08/2002)
Another significant concern with
complementary medicines is that
they are, by their nature, self-admin-
istered and consequently patients
may not seek medical advice for
potentially severe medical condi-
tions.
Other causes of adverse reactions
may be the consumption of products
such as infusions of comfrey, which
may contain pyrrolizidine alkaloids. 
Complementary therapies them-
selves rather than complementary
medicines have also been a cause of
adverse events. Most of the adverse
Table 4.  F indings from the TGA’s investigations into the Austral ian
manufacturer  (12)
•  Misidentification of raw material, especially herbal materials, which could lead to
severe organ damage, including renal and hepatic damage 
•  Cross-contamination or substitution of ingredients due to inadequate operating
procedures and poor compliance with existing procedures could lead to severe al-
lergic reactions including anaphylaxis
•  Microbiological contamination through poor raw material sourcing and handling,
poor cleaning practices, and inadequate operating procedures, potentially leading
to infections
•  Substitution of shark cartilage for bovine cartilage which could cause seroius aller-
gic reactions, including anaphylaxis, in fish-protein sensitive individuals
•  Substitution of bovine cartilage for shark cartilage where the bovine cartilage has
been sourced without any assurance that it is TSE-free, and the country of origin is
unknown
•  Bovine colostrum obtained from non-approved suppliers where the raw material
may have been sourced from a TSE ‘at risk’ country, and where the source is un-
known
•  Manipulation of assay results of finished products in order to comply with specifi-
cations
•  Fabrication of assay results of a finished vitamin product for export in order to
comply with specifications
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effects are associated with acupunc-
ture and include systemic infections,
endocarditis, septicemia, hepatitis B,
HIV, osteomyelitis, myositis, peri-
tonitis and pleural emphysema (13).
Complementary and Western
medicines
It has been well documented that
complementary medicines can inter-
act with western medicines, these
interactions can cause adverse
effects. The concurrent use of com-
plementary and western medicine is
reported to be as high 30% in Aus-
tralia (7). Therefore based on this
estimate as many as 1.8 million to 4
million Australians may be effected
by such interactions in 2004 (14). 
The potential for adverse effects
including interactions is compound-
ed by the patients not disclosing the
use of complementary medicines to
their doctors. An American study
revealed that 63–72% of patients
did not tell their doctors about their
use of complementary medicines and
therapies (15). Reasons given by the
patients included “it’s not important
for the doctor to know” (61%),
“the doctor never asked” (60%) “it
was none of the doctors’ business”
(31%) and “the doctor would not
understand” (20%). In Australia
also the reported level of undis-
closed concurrent use of comple-
mentary medicines with western
medicine is as high as 57% (7). 
“Bush medicine”
Traditional medicines derived from
the Australian aborigines have
received relatively little attention.
The Australian aboriginal medicine
is more commonly referred to as
bush medicine. The Australian abo-
riginal people have a holistic view
towards health and the following
definition has been adopted by the
National Aboriginal Health Strategy
(NAHS) health is “not just the phys-
ical but the social emotional and
cultural well being of the whole
community. This is the whole-of-life
view and it also includes the cyclical
concept of life-death-life.” 
Australian aborigines have occu-
pied the land for over 40,000 years
and over time they have acquired
good knowledge of their surround-
ings and the benefits of the flora and
fauna. Webb (16) showed that many
of the traditional bush medicines did
in fact contain biologically active
constituents.  Several examples
include Bitter Bark (Alstonia con-
stricta) which contains reserpine (a
tranquilliser and antihypertensive)
and the Native Daisy (Spilanthe
spp.) which contains anaesthetic spi-
lanthol. 
Over half the world’s supply of
the drugs hyoscine and scopolamine
come from the Australian native tree
Duboisia, which has been tradition-
ally used by aborigines as an emu
and fish poison (17). There are cer-
tain to be many other bush medi-
cines that are yet to be investigated,
however much of the aboriginal tra-
ditional knowledge may have been
lost in more recent times.
Regulation of complementary
medicines
The product mobility and interna-
tional access to products makes reg-
ulation of these products difficult.
While in some countries, comple-
mentary medicines are subject to rig-
orous manufacturing standards, this
is not so everywhere. In the USA
most herbal products are marketed
and regulated as dietary supple-
ments. This means that products do
not require approval under the Fed-
eral Food, Drug, and Cosmetic Act.
The only requirement is that these
products meet the standards of the
1994 Dietary Supplement and
Health Education Act. This means
that herbal products are not regulat-
ed by the Food and Drug Adminis-
tration (FDA) and are not manufac-
tured to comply with Good Manu-
facturing Practice (GMP). Under the
relevant act claims can be made that
a product affects the structure or
function of the body, as long as
there is no claim of effectiveness for
the prevention or treatment of a spe-
cific disease. 
In sharp contrast to the USA, in
Germany for example, where herbal
products are sold as phytomedicines,
they are subject to the same criteria
for efficacy, safety and quality assur-
ance as are other medicinal prod-
ucts. 
In April 2004, the European
Union introduced Directive
2004/24/EC on Traditional Herbal
Medicinal Products (18). This direc-
tive requires traditional herbal medi-
cines to meet specific standards of
safety and quality and for the prod-
ucts to be accompanied by the nec-
essary information for the product
to be used safely. The normal
requirement for medicines to
demonstrate efficacy will be
replaced by a requirement to
demonstrate traditional use. 
Regulation in Australia
Australia is one of few individual
countries to have implemented
reforms in the area of complemen-
tary medicine. The Complementary
Medicines Reform Package was
released in January 1999. It was
designed to provide more timely
market access for complementary
healthcare products, while continu-
ing to ensure that products are safe,
of high quality, and that they do
what they claim they will do. 
The reform packages has two
key policies review of advertising
arrangements, including the code
and guidelines; and enhancement of
post-market vigilance.
The Office of Complementary
Medicines (OCM) is a body within
the Therapeutic Goods Administra-
tion (TGA) that regulates comple-
mentary healthcare products. Anoth-
er body, the Complementary Health-
care Consultative Forum (CHCF) is
a high level forum aimed at facilitat-
ing consultation between govern-
ment, the complementary health
care industry and consumers.  
In Australia, the TGA regulates
proprietary medicines which
includes complementary medicines.
This means that all products sold
must be listed or registered with the
TGA and labelled with an “AustL”
or “AustR” number. (AustL prod-
ucts have been assessed for quality
and safety, AustR products have
been assessed for quality, safety and
efficacy). In December 1997 the
Complementary Medicines Evalua-
tion Committee (CMEC) was estab-
lished. This is an expert committee
that evaluates and reviews new com-
plementary medicines and new sub-
stances for complementary health-
care products.
Whilst the products are regulated
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by the Federal Government, the
States and Territories regulate prac-
titioners. The Chinese Medicine
Registration Act 2000 was passed
by the Victorian Parliament. In pass-
ing this act, Victoria became the first
state to introduce statutory regula-
tion of Chinese medicine. Currently
New South Wales is reviewing their
regulations of Chinese Medicine. 
Health insurance and comple-
mentary medicines
The extent of financial contributions
by health insurance bodies is rele-
vant to the availability and use of
complementary medicines. Expenses
for complementary medicines are
generally covered by the patient in
Australia. Private health insurance
may cover the cost of some treat-
ments and therapies though this is
predominately limited to chiroprac-
tic, naturopathic, osteopathic and
registered practitioners of traditional
Chinese medicine. Medicare (pub-
licly funded healthcare) will cover
the cost of acupuncture if it is part
of a doctors’ consultation. 
Final thoughts
In spite of the regulatory efforts of a
number of countries, the safety of
the products used by consumers can-
not be guaranteed. Domestically
produced products may be relatively
well regulated. However, internet
sales and private import of these
products have changed the whole
landscape. It is now so easy to
obtain products from ill-defined
sources that in many cases the
efforts of local regulation are signifi-
cantly compromised. In addition the
international discrepancies in regula-
tion contribute to consumer confu-
sion. 
Major issues continue to be asso-
ciated with the use of complemen-
tary medicines. These include public
perception that natural products are
inherently safe. With the increased
use of a wide range of complemen-
tary medicines it is possible that pre-
viously unrecognised or delayed toxi-
city may emerge and it is certain that
there will be increasing numbers of
interactions between complementary
and conventional medicines. 
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Namweb search – up-to-date information on drugs
The search facility for medicinal products is a free service available to all. It can be used for searching information
both on human and veterinary medicinal products with marketing authorisation. The service also provides  informa-
tion of availability on the market. 
The various links will open up summaries of product characteristics (SPC) and package information leaflets (PIL) and
synonyme medicinal products in accordance with their ATC code. The search facility can also be used for looking up
information on medicinal products recommended not to be used when driving, and on medicines associated with pre-
scription or distribution restrictions.
In addition to information covering approximately 6,400 products with marketing authorisation, about 5,500 whose
marketing authorisations have been withdrawn are also included. The information is updated daily. The search facility
is also available in English (http://namweb.nam.fi/namweb/do/haku/view?locale=en). 
New structure and layout with news items for each target group
The pharmaceutical industry, pharmacies, healthcare professionals and users of medicines will find that the contents
of the website and news of particular interest to them are targeted individually for each group. New features of inter-
est to the pharmaceutical industry include issues on biological medicinal products and medical treatment of children,
and new features intended for the consumers include traveller’s medicines.
Topics of current interest include news and press releases issued. The opening screen always contains the ten most re-
cently published topics, and more news items of current interest may also be found by using the search facility provid-
ed for each target group.
In addition to the sections for each target group, the website contains sections for information on medicines, legisla-
tion, medical devices, and publications and information about the operations of the Agency. You may also order pub-
lications, give feedback and inform the Agency about your new contact details by using the feedback form provided. 
Katja Lindgren-Äimänen
Renewed website offers new services www.nam.fi
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